Cambridge Retirement System v. Slavko James Joseph Bosnjak

CourtCourt of Chancery of Delaware
DecidedJune 26, 2014
DocketCA 9178-CB
StatusPublished

This text of Cambridge Retirement System v. Slavko James Joseph Bosnjak (Cambridge Retirement System v. Slavko James Joseph Bosnjak) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cambridge Retirement System v. Slavko James Joseph Bosnjak, (Del. Ct. App. 2014).

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

CAMBRIDGE RETIREMENT SYSTEM, ) derivatively on behalf of Unilife Corporation, ) ) Plaintiff, ) v. ) C.A. No. 9178-CB ) SLAVKO JAMES JOSEPH BOSNJAK, ) JEFF CARTER, JOHN LUND, WILLIAM ) GALLE, MARY KATHERINE WOLD, ) MARC FIRESTONE, and ALAN ) SHORTALL, ) ) Defendants, ) ) and ) ) UNILIFE CORPORATION, ) ) Nominal Defendant. )

MEMORANDUM OPINION

Date Submitted: June 9, 2014 Date Decided: June 26, 2014

Christine S. Azar and Ned Weinberger of Labaton Sucharow LLP, Wilmington, Delaware; Christopher J. Keller, Eric J. Belfi and Michael W. Stocker of Labaton Sucharow, New York, New York, Attorneys for Plaintiff.

M. Duncan Grant and James G. McMillan, III of Pepper Hamilton LLP, Wilmington, Delaware; Jay A. Dubow of Pepper Hamilton, Philadelphia, Pennsylvania, Attorneys for Defendants.

BOUCHARD, C. I. INTRODUCTION

This action involves derivative claims for breach of fiduciary duty (Count I) and

corporate waste (Count II) concerning compensation paid to the non-executive directors

of Unilife Corporation (“Unilife” or the “Company”) since November 2010. The

challenged compensation consists of two components: (1) equity awards the Unilife

directors granted to themselves subject to obtaining stockholder approval for those

awards and (2) cash compensation the directors paid to themselves without obtaining

stockholder approval.

Unilife has moved to dismiss the complaint for failure to make a pre-suit demand

upon the Unilife board of directors or to plead facts that excuse such a demand and, as to

certain claims, for failure to state a claim upon which relief may be granted. For the

reasons set forth below, I conclude that demand is excused under the first prong of

Aronson because the claims involve self-dealing transactions implicating a majority of

the members of Unilife’s board of directors at the time suit was filed. I also conclude that

the fiduciary duty claim should be dismissed for failure to state a claim for relief insofar

as it relates to the outside directors’ equity awards because each of those awards was

specifically approved by Unilife’s stockholders and that the corporate waste claim fails to

satisfy the stringent standard for stating such a claim. Defendants did not seek to dismiss

the fiduciary duty claim for failure to state a claim for relief insofar as that claim relates

to cash compensation paid to the directors for their services as directors. Thus, that claim

survives.

1 II. BACKGROUND1

A. The Parties

Unilife is a manufacturer and supplier of injectable drug delivery systems,

including retractable syringes. In 2002, the Company was founded in Sydney, Australia.

In 2008, Unilife moved its operations to York, Pennsylvania. In 2010, Unilife

redomiciled from Australia to the State of Delaware and became listed on the NASDAQ

Global Market.

Since its formation in 2002, Unilife has failed to turn a profit or to generate

significant revenues. During its last three fiscal years,2 Unilife’s revenues declined from

$6.7 million in fiscal year 2011, to $5.5 million in fiscal year 2012, to $2.7 million in

fiscal year 2013. During this same period, the Company incurred losses of $40.7 million

in fiscal year 2011, $52.3 million in fiscal year 2012 and $63.2 million in fiscal year

2013.

1 Unless otherwise noted, the facts recited in this Memorandum Opinion are based on the allegations in plaintiff’s complaint, documents integral to or incorporated in the complaint, or facts of which the Court may take judicial notice. Plaintiff acknowledges that the Company’s 2010 to 2013 proxy statements are incorporated by reference into its complaint. Pl.’s Answering Br. 7. 2 Unilife’s fiscal year runs from July 1 to June 30. For example, its fiscal year 2011 ended on June 30, 2011.

2 Plaintiff Cambridge Retirement System is a Massachusetts-based retirement

system. It has held Unilife common stock continuously since November 2010, and

challenges the compensation paid to Unilife’s outside directors during this period.3

From November 2010 until November 2012, Unilife’s board of directors had

seven members, consisting of its Chairman and Chief Executive Officer, Alan Shortall,

and six outside directors: Slavko James Joseph Bosnjak, Jeff Carter, John Lund, William

Galle, Mary Katherine Wold and Marc Firestone. Firestone left the board in November

2012. As of the date the complaint in this action was filed on December 20, 2013, the

board consisted of six directors: Shortall, Bosnjak, Carter, Lund, Galle and Wold.

B. Non-Management Director Compensation

During the period at issue, Unilife compensated its outside directors through a

combination of equity awards and cash compensation. Significant to the pending motion,

the Unilife board conditioned its grant of each of the challenged equity awards on

obtaining stockholder approval, which the stockholders provided.

On January 8, 2010, in connection with Unilife’s redomiciliation from Australia to

the State of Delaware, the Company’s stockholders approved the adoption of its 2009

Stock Incentive Plan (the “2009 Plan”).4 Thereafter, on two separate occasions, the

3 In the face of a challenge to its standing to assert claims concerning compensation paid to the outside directors before November 2010, Cambridge explicitly disclaimed any intention to seek repayment of such compensation. Pl’s Answering Br. 7, n.7. 4 Defs.’ Opening Br. Ex. F at 24, 38, 49 (Unilife Corp., Amended Registration Statement (Form 10) (Feb. 11, 2010)).

3 stockholders approved specific equity awards that the directors had granted themselves

under the 2009 Plan conditioned on the receipt of stockholder approval.

At a stockholders’ meeting held on December 1, 2010, Unilife’s stockholders

approved grants of options to directors Wold and Firestone to purchase 100,000 shares of

common stock each under the 2009 Plan.5 These grants were the subject of two

proposals (Proposals No. 3-4) for stockholder approval described in a proxy statement

dated October 18, 2010.

Proposal No. 3 explained that the 100,000 options for Wold would have an

exercise price of $6.83 per share based on the closing price of the Company’s shares on

May 11, 2010 (the date the Unilife board approved the grant), would be exercisable for

five years and would vest as follows: 16,667 options would vest within three business

days of the Company obtaining stockholder approval, 25,000 shares would vest on the 12

month anniversary and 24 month anniversary of the date of grant and 33,333 shares

would vest on the 36 month anniversary of the date of grant. Proposal No. 4 provided the

same information concerning the 100,000 options for Firestone except that they would

have an exercise price of $6.19 per share based on the closing price of the Company’s

shares on July 27, 2010, the date the Unilife board approved the grant.6 The proxy

statement also disclosed that the common stock underlying the options for Wold and

5 Defs.’ Opening Br. Ex. B at 39-40 (Unilife Corp., Definitive Proxy Statement (Form 14A) (Oct. 14, 2011)). 6 Defs.’ Opening Br. Ex. A at 15-16 (Unilife Corp., Definitive Proxy Statement (Form 14A) (Oct. 18, 2010)).

4 Firestone have a “market value” of $683,000 and $619,000, respectively, based on the

closing price of the Company’s common stock on the date Unilife’s board approved each

grant.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Beam Ex Rel. Martha Stewart Living Omnimedia, Inc. v. Stewart
833 A.2d 961 (Court of Chancery of Delaware, 2003)
Cinerama, Inc. v. Technicolor, Inc.
663 A.2d 1156 (Supreme Court of Delaware, 1995)
Beam Ex Rel. M. Stewart Living v. Stewart
845 A.2d 1040 (Supreme Court of Delaware, 2004)
Desimone v. Barrows
924 A.2d 908 (Court of Chancery of Delaware, 2007)
Orman v. Cullman
794 A.2d 5 (Court of Chancery of Delaware, 2002)
Kerbs v. California Eastern Airways, Inc.
90 A.2d 652 (Supreme Court of Delaware, 1952)
Zupnick v. Goizueta
698 A.2d 384 (Court of Chancery of Delaware, 1997)
Meiselman v. Eberstadt
170 A.2d 720 (Court of Chancery of Delaware, 1961)
Wilderman v. Wilderman
315 A.2d 610 (Court of Chancery of Delaware, 1974)
Sinclair Oil Corporation v. Levien
280 A.2d 717 (Supreme Court of Delaware, 1971)
O'REILLY v. Transworld Healthcare, Inc.
745 A.2d 902 (Court of Chancery of Delaware, 1999)
HMG/Courtland Properties, Inc. v. Gray
749 A.2d 94 (Court of Chancery of Delaware, 1999)
Telxon Corporation v. Meyerson
802 A.2d 257 (Supreme Court of Delaware, 2002)
Harbor Finance Partners v. Huizenga
751 A.2d 879 (Court of Chancery of Delaware, 1999)
Hall v. John S. Isaacs & Sons Farms, Inc.
163 A.2d 288 (Supreme Court of Delaware, 1960)
In Re the Walt Disney Co. Derivative Litigation
731 A.2d 342 (Court of Chancery of Delaware, 1998)
Cede & Co. v. Technicolor, Inc.
634 A.2d 345 (Supreme Court of Delaware, 1994)
In Re Walt Disney Co. Derivative Litigation
906 A.2d 27 (Supreme Court of Delaware, 2006)
Gantler v. Stephens
965 A.2d 695 (Supreme Court of Delaware, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
Cambridge Retirement System v. Slavko James Joseph Bosnjak, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cambridge-retirement-system-v-slavko-james-joseph--delch-2014.